Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016

  • ID: 3788879
  • Report
  • 46 pages
  • Global Markets Direct
1 of 6
Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016

Summary

‘Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016’, provides in depth analysis on Glial-Derived Neurotrophic Factor (GDNF) targeted pipeline therapeutics.

The report provides comprehensive information on the Glial-Derived Neurotrophic Factor (GDNF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glial-Derived Neurotrophic Factor (GDNF)
- The report reviews Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glial-Derived Neurotrophic Factor (GDNF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glial-Derived Neurotrophic Factor (GDNF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Glial-Derived Neurotrophic Factor (GDNF) Overview

Therapeutics Development

Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Stage of Development

Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Therapy Area

Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Indication

Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Companies

Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Universities/Institutes

Glial-Derived Neurotrophic Factor (GDNF) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glial-Derived Neurotrophic Factor (GDNF) - Companies Involved in Therapeutics Development

NsGene A/S

UniQure N.V.

Glial-Derived Neurotrophic Factor (GDNF) - Drug Profiles

AMT-090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAUR-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NsG-0301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smilagenin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glial-Derived Neurotrophic Factor (GDNF) - Dormant Projects

Glial-Derived Neurotrophic Factor (GDNF) - Featured News & Press Releases

Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy

Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane

Feb 18, 2013: Phytopharm Announces Results From Parkinson’s Disease Clinical Trial Of Cogane

Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis

Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson’s Disease

Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis

Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study

Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis

Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status

Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease

Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane

Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson’s Disease

Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane

Jun 05, 2007: Phytopharm plc Presents Cogane Data At ‘11th International Congress Of Parkinson’s Disease And Movement Disorders’

Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 46List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by NsGene A/S, H1 2016

Pipeline by UniQure N.V., H1 2016

Dormant Projects, H1 2016 33List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Glial-Derived Neurotrophic Factor (GDNF) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Glial-Derived Neurotrophic Factor – Pipeline Review, H1 2016, outlays comprehensive information on the Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glial-Derived Neurotrophic Factor (GDNF) Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
NsGene A/S
UniQure N.V.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll